|Company name||Intersect ENT, Inc.|
|Class period||August 1, 2018 – May 6, 2019|
|Court||Northern District of California|
NEW YORK, July 8, 2019 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Intersect ENT, Inc. (NASDAQ: XENT) securities between August 1, 2018 and May 6, 2019 (the “Class Period”). Investors have until July 15, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, the complaint alleges that defendants failed to disclose to investors that: (1) the company lacked adequate reimbursement representatives to ensure physicians had access to SINUVA; (2) as a result, the company’s sales force would focus on ensuring reimbursement; (3) as a result, the company’s sales representatives were less focused on driving sales; (4) physicians were less likely to adopt the company’s SINUVA due to transaction costs associated with seeking reimbursement; (5) the company would increase staffing to address these issues; and (6) as a result of the foregoing, defendant’s positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you purchased Intersect securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.